Robert E. Andreatta - May 15, 2025 Form 4 Insider Report for Allakos Inc. (ALLK)

Role
Director
Signature
/s/ H. Baird Radford, III, by power of attorney
Stock symbol
ALLK
Transactions as of
May 15, 2025
Transactions value $
$0
Form type
4
Date filed
5/15/2025, 04:01 PM
Previous filing
May 29, 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Andreatta Robert E Director 149 COMMONWEALTH DR, SUITE 1090, MENLO PARK /s/ H. Baird Radford, III, by power of attorney 2025-05-15 0001396785

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLK Stock Option (right to buy) Disposed to Issuer $0 -37.6K -100% $0.00 0 May 15, 2025 Common Stock 37.6K $16.00 Direct F1
transaction ALLK Stock Option (right to buy) Disposed to Issuer $0 -16K -100% $0.00 0 May 15, 2025 Common Stock 16K $40.00 Direct F1
transaction ALLK Stock Option (right to buy) Disposed to Issuer $0 -7.7K -100% $0.00 0 May 15, 2025 Common Stock 7.7K $72.54 Direct F1
transaction ALLK Stock Option (right to buy) Disposed to Issuer $0 -7.7K -100% $0.00 0 May 15, 2025 Common Stock 7.7K $99.83 Direct F1
transaction ALLK Stock Option (right to buy) Disposed to Issuer $0 -99.6K -100% $0.00 0 May 15, 2025 Common Stock 99.6K $2.62 Direct F1
transaction ALLK Stock Option (right to buy) Disposed to Issuer $0 -86.8K -100% $0.00 0 May 15, 2025 Common Stock 86.8K $4.81 Direct F1
transaction ALLK Stock Option (right to buy) Disposed to Issuer $0 -41K -100% $0.00 0 May 15, 2025 Common Stock 41K $1.42 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Robert E. Andreatta is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This option was cancelled without consideration pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc.